Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01549223 · ClinicalTrials.gov registry record · Phase 4
Oxytocin And Uterotonic Agent Use For Cesarean Delivery
A Phase 4 study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
NCT01549223 is a Phase 4 study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 60 participants.
The verdict
NCT01549223, a Phase 4 study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
Study Summary
The central objective of this study will be to evaluate a standardized, evidence-based regimen versus a conventional regimen for uterotonic drug dosing for elective cesarean delivery The investigators primary hypothesis is that the proposed uterotonic drug regimen, when compared to conventional dosing regimen, during elective cesarean delivery will: 1\. Reduce the overall amount of oxytocin and other uterotonic agents used to obtain satisfactory uterine tone. Secondary outcomes to be evaluated will be: 1. Reduce the side effects associated with uterotonic drug use 2. Reduce the time to establishment and maintenance of adequate uterine tone
Interventions
- DRUG Oxytocin Infusion
- DRUG Oxytocin Bolus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2011-04 |
| Est. Completion | 2012-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01549223
The ClinicalTrials.gov registry entry for NCT01549223 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Oxytocin Infusion is the first listed.
NCT01549223 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01549223 about?
NCT01549223 is a clinical study titled "Oxytocin And Uterotonic Agent Use For Cesarean Delivery". The central objective of this study will be to evaluate a standardized, evidence-based regimen versus a conventional regimen for uterotonic drug dosing for elective cesarean delivery The investigators primary hypothesis is that the proposed uterotonic drug regimen, when compared to conventional dos...
What is the current status of trial NCT01549223?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2011-04. Estimated completion is 2012-01.
What interventions are being tested in trial NCT01549223?
The interventions under investigation include: Oxytocin Infusion (DRUG), Oxytocin Bolus (DRUG).
Who is sponsoring clinical trial NCT01549223?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.